4 Key Drug Approvals Expected In The Next 30 Days | Pharmaceutics_R&D | Scoop.it

Biogen Idec's BG-12, United Therapeutics' oral Remodulin, Johnson & Johnson's Invokana and Allergan's Levadex are all nearing their possible launches

Investing in drug stocks isn't quite like investing in other stocks. While drugmakers' shares can move on earnings and buyout news like anyone else's, what really gets investors excited is an FDA decision allowing a new drug on the market. Here are some of the most important drugs awaiting approval in the next month. (...) - by Amy Reeves, Investors.com, 03/15/2013